Literature DB >> 18981530

Multiple treatments with SRIH-14 or octreotide affect adrenal zona glomerulosa in adult male rats.

S Trifunović1, V Ajdzanović, B Sosić-Jurjević, B Filipović, N Nestorović, M Sekulić, V Milosević.   

Abstract

Somatostatin analogues are currently used to treat various disorders such as hypersecretion and different neuroendocrine tumors. In this study we examined the effects on the adrenal cortex of somatostatin (SRIH-14) and octreotide administered subcutaneously twice daily for 5 days to adult male rats. Control rats received saline under the same regime. After sacrifice, the adrenal glands were removed and examined morphometrically using the M(42) multipurpose test system. Blood samples were prepared for biochemical tests. Both SRIH-14 and octreotide induced morphofunctional changes in adrenal zona glomerulosa. We found significant decreases (p < 0.05) in the absolute cell and nuclear volumes of zona glomerulosa in both experimental groups in comparison to the control. The serum aldosterone level was 11% lower (p < 0.05) in the SRIH-14 and 13% (p < 0.05) lower in the octreotide-treated group in comparison with the control group. Morphometric parameters of zona fasciculata and zona reticulata and corticosterone levels were not altered significantly (p > 0.05) in either treated group. It may therefore be concluded that both SRIH-14 and octreotide affected zona glomerulosa in the same manner by decreasing morphofunctional characteristics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18981530

Source DB:  PubMed          Journal:  Gen Physiol Biophys        ISSN: 0231-5882            Impact factor:   1.512


  1 in total

1.  Demystifying "Steroid Withdrawal" During Remission in Cushing's Disease: Is Mineralocorticoid Replacement the Answer?

Authors:  Nimisha Jain; K Mahesh Kumar; Naresh Sachdeva; Anil Bhansali; Rama Walia
Journal:  Indian J Endocrinol Metab       Date:  2019 Jul-Aug
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.